Obesity is a condition often linked with various health issues, including musculoskeletal disorders, which can lead to impaired mobility and increased frailty. This study investigates the effects of a multidisciplinary obesity management program that incorporates semaglutide on gait speed and physical function in a real-world setting.
Study Overview
This retrospective observational study involved 22 adults diagnosed with obesity and musculoskeletal disorders who participated in a 12-month program. The program included regular nutritional counseling, guided exercise interventions by physical therapists, and treatment with semaglutide.
Key Findings
- Weight Loss: Participants experienced a significant reduction in body weight, from an average of 89.2 kg to 81.5 kg (p<0.001).
- Gait Speed Improvement: The usual gait speed improved from 0.77 m/s to 0.91 m/s (p<0.001).
- Pain Reduction: Pain scores also showed significant improvement (p<0.001).
Interestingly, the study found that improvements in gait speed were not directly associated with weight loss or pain reduction. Instead, participants with poorer baseline mobility showed greater gains in gait speed, suggesting that the program may be particularly beneficial for those with more significant mobility impairments.
What this study does not show
While the study indicates improvements in gait speed and weight loss, it does not establish a direct causal relationship between semaglutide treatment and these outcomes, nor does it provide insights into long-term effects beyond the 12-month period.
Evidence scorecard
- Analytic validity: established
- Clinical validity: established
- Clinical utility: not established
The evidence is based on a primary research study involving human participants.